🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Calling for #HTTR24 abstracts that dive deep into the mechanisms, biomarkers, & models that drive our understanding & treatment of drug tolerance & resistance in #NSCLC. Share your groundbreaking research & contribute to the future of #lungcancer therapy. bit.ly/HTTR24AS

Enjoyed sharing our work on ERBB2 mutations in Lung Cancer with a Merit Award from Conquer Cancer, the ASCO Foundation! Thanks to PS for spearheading this effort, Michael Grant @politikaterina #SarahGoldberg for the immense mentorship and to Yale IM Traditional Residency Program for their support! #ASCO24

In case you missed it, #ASCO24 is officially rebranded as #ASCOLung 😂 Especially because this amazing human Jill Feldman was awarded patient advocate of the year! We love you so much!! 🤍 ASCO Fawzi Abu Rous, MD LungCancerRx 🫁💊

Dana-Farber in the wild: Marc Machaalani, MD, (Marc Machaalani) of the Lank Center (Dana-Farber Lank Center for Genitourinary Oncology) presents data on the prevalence of ERBB2 mutations in urothelial carcinoma. #ASCO24

Why do some patients benefit less than others from precision cancer medicine? We are excited to share our paper "Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling” out in Nature Communications. nature.com/articles/s4146… 🧵

Check out our Resource paper published today in Cell Reports Cell Press on the epigenetic features of sarcomatoid RCC! Effort led with co-first Karl Semaan, MD, MSc with great mentorship from Sylvan Baca MD PhD (Hiring!) #MattFreedman Toni Choueiri, MD and co-authors! Link: cell.com/cell-reports/f…

Finally, our long-awaited first year fellows are here! We are so excited to add this crew to our family and can not wait to watch them all shine! Let's go class of 2027!

Day made thanks to ASCO TECAG ASCO for providing a platform for young trainees at #ASCO24 as we presented our work from Yale Internal Medicine Yale Cancer Center PS Michael Grant! Fernando Diaz, MD @jacobadashek

It might take us a second to coordinate getting a group picture, but it's because we just like each other. And we certainly love our first year fellows class! It was a joy learning about each of you at the Heme-Onc Fellows Welcome Party. You already make our family richer. 💙

It is not quite 2 months since our first year fellows started fellowship and what a brilliant group it is. Case and point is Dr. Casasanta who excelled on one of our toughest services, hematology consults with her attending stating "Nicole is a rockstar." Oh we know 💫🤟!

Highly recommended program for fellows and early-career. I met some of the best colleagues and #mentors in #lcsm Eric K. Singhi, MD Joshua Reuss PS Stephen V Liu, MD Jill Feldman Lecia Sequist, MD, MPH

Our goal is to help early career investigators foster collaborations early in their careers and support their important work. YOU are our future. Please share with early investigators you know! Submit your abstract for the #EGFRSummit Don’t miss the the 9/30 deadline!

Why Yale? A Thread by our Program Director Dr. Siegel Mark D. Siegel We are sharing the whole letter here to make sure all our applicants will get a chance to read it. 🧵🧵

Slide updated ✅ Oncology Brothers OncoAlert #lcsm

2/2 🫁 Stage III - Unresectable NSCLC 🫁 🌟 Treatment algorithm 🌟 Chemoradiation therapies 🌟 Consolidation therapies

A must-read Review on the ever-evolving field of #EGFR mut #NSCLC in@NatRevClinOncol highlighting: ➡️Strategies to improve on 1L 3rd Gen TKI mono therapy ➡️ Ways to tackle resistance post-Osi ➡️Perioperative landscape Xiuning Le MD PhD Daniel Tan Suresh S. Ramalingam, MD, FASCO IASLC #LCSM #some

📖 👉New online: Nature Portfolio Review Clinical Oncology. 2024 marks the 20th anniversary of the discovery of #EGFR in #NSCLC. rdcu.be/d1V2Q Osimertinib represents just one of many significant advancements, as a community IASLC, we have: 1. Over 10 approved

Great posters at #HTTR24 from fellows Drs. PS and Brinda Gupta exploring aspects of #EGFR NSCLC resistance such as role of tumor suppressors and the expression of #SEZ6 in SCLC transformation. And both are alumni of the EGFR Resisters Research Summit!

Another ALK inhibitor (#ensartinib) gets U.S. FDA approval eXalt3 study: - 1L, Ph III, ALK+ mNSCLC vs Crizotinib - Ensartinib vs crizotinib (NR vs 12.7mos, HR: 0.45) - CNS ORR 64% w/ ensartinib vs 21% - AES: rash, 💪 pain, nause #OncTwitter #MedTwitter OncoAlert

ADC’s Bystander Effect may be crucial for efficacy! In a provocative recent paper, HER2 ADC’s payload may not need ADC internalization for efficacy ! Activity may rely on extracellular proteases, such as cathepsin L (CTSL). This extracellular release in the TME appears to kill